Navigation Links
Abide Therapeutics Appoints Nancy Thornberry to Board of Directors

SAN DIEGO, July 29, 2014 /PRNewswire/ -- Abide Therapeutics announced today the appointment of Nancy Thornberry to its board of directors. Thornberry was previously senior vice president and franchise head, Diabetes and Endocrinology for Merck & Co. Inc., where she led discovery, clinical research, strategy and overall pipeline management in diabetes, osteoporosis, fertility and contraception. Thornberry, a distinguished pharmaceutical scientist, initiated and co-led the program that resulted in the discovery of JanuviaTM, an inhibitor of DPP-4, a serine hydrolase, for the treatment of type 2 diabetes. Abide has pioneered innovative technologies to selectively target serine hydrolases, one of the largest enzyme families involved in regulating human physiology.

"Nancy has been an invaluable member of our scientific advisory board," said Alan Ezekowitz, MBChB, D.Phil., president and CEO of Abide Therapeutics. "As we advance our programs into the clinic, Nancy's in-depth knowledge of drug discovery and development will be invaluable. Additionally, her expertise in the serine hydrolase space will be advantageous in advising the Company on target selection and validation."

"As a member of Abide's scientific advisory board for the past year, I have seen firsthand the potential of Abide's disruptive technologies and the talent of the Company's team," said Thornberry. "As many know, DPP-4 is a member of the serine hydrolase family and inhibitors of this enzyme have proven to be important in the treatment of type 2 diabetes. With more than 200 members, the serine hydrolase family is involved in many key aspects of human physiology and disease. As a member of the board of directors, I look forward to helping Abide reach the full potential of their unique and powerful approach to target a validated but largely underexplored class of enzymes."

Nancy Thornberry began her long and distinguished career at Merck Research Laboratories (MRL) in 1979 as a biochemist. Among her most notable accomplishments are the identification of the first caspase, interleukin-1B converting enzyme (ICE/caspase-1), and development of a novel approach for the analysis of protease specificities. In 1999, she initiated the dipeptidyl peptidase 4 (DPP-4) program and co-led the team that led to the discovery of Januvia (sitagliptin). In 2007, Thornberry became a vice president and Worldwide Basic Research Head for Diabetes and Obesity, and was promoted in 2009 to SVP and franchise head of Diabetes and Obesity. In 2011, Thornberry became SVP and franchise head of Diabetes and Endocrinology. She has been an author on numerous publications and received a number of awards for her accomplishments, including the PhRMA's Discoverers Award, which honors research scientists whose work has been of special benefit to humankind. 

About Serine Hydrolases

The large family of serine hydrolases are validated but largely underexplored as drug targets. These enzymes play a key regulatory role in human physiological processes, such as regulating CNS signaling, digestion, metabolism, inflammation, blood clotting, and life cycle of viruses and pathogens. Thus, the ability to target serine hydrolases has broad therapeutic applications. The proprietary Abide technology platform provides a unique highly selective small molecule collection that specifically targets the common catalytic site of serine hydrolases. The technology provides a rapid and effective method for target identification and validation. 

About Abide Therapeutics

Abide Therapeutics is focused on developing innovative medicines that target serine hydrolases, one of the largest enzyme classes in nature with validated but mostly untapped therapeutic potential. Serine hydrolases play important regulatory roles in human physiology and disease. Abide has created a proprietary platform, based on technology developed at The Scripps Research Institute by Professors Ben Cravatt and Dale Boger, that specifically targets serine hydrolases with selective small molecules. The ability to target and modulate serine hydrolases has potential to develop new medicines in many therapeutic areas. Abide is located in San Diego. To learn more, visit

SOURCE Abide Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Abide Therapeutics Announces Collaboration With Merck to Develop Novel Therapies for Type 2 Diabetes and Metabolic Diseases
2. Abide Therapeutics Appoints Dr. Gary ONeill as Vice President of Biology
3. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
4. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
5. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
8. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
9. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
10. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
11. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
Breaking Medicine Technology:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):